NHS unveils state-of-the-art center for cell and gene therapy innovation and production

UNITED KINGDOM — The U.K.’s National Health Service Blood and Transplant (NHSBT), responsible for managing blood and platelet donations, as well as organ, stem cell, and tissue transplants, has launched a new clinical biotech center located in Filton, North Bristol.

Its purpose is to increase the U.K.’s production capacity for DNA plasmids and viral vectors, crucial components for gene therapies and genetically modified cell therapies.

This facility will also facilitate early-stage clinical trials and preclinical research, according to a press release by the agency on March 10.

The NHSBT stated that the construction of the site was part of its efforts to address the country’s limited ability to manufacture the necessary materials for these innovative therapies.

Lilian Hook, Ph.D., NHSBT’s director of cell, apheresis, and gene therapies, expressed her excitement about the potential for cutting-edge research and the ability to create potential cures for diseases that currently have no cure and often prove fatal.

The facility was made possible by a government grant of 10 million pounds sterling (US$10.7 million).

The COVID-19 pandemic that emerged in early 2020 has created an unprecedented need for new and innovative cell and gene therapies.

The pandemic has underscored the importance of developing therapies that can effectively combat infectious diseases and mitigate the effects of chronic conditions.

Consequently, the demand for such therapies has skyrocketed, necessitating a significant expansion of cell therapy production facilities.

The U.K. government had already recognized the need to invest in the biotech industry before the pandemic.

In 2012, it established the Cell and Gene Therapy Catapult, an initiative aimed at addressing the declining number of pharmaceutical manufacturing sites in the country.

The group’s efforts paid off, and in 2015, it announced plans to construct a US$85 million cell manufacturing facility to enhance the country’s biotech capabilities.

In light of the COVID-19 pandemic, however, the need for cell therapy production facilities has grown even more acute.

The new NHSBT site in Filton, North Bristol, is a crucial addition to the country’s efforts to meet this need.

This facility will play a vital role in supporting the early-stage clinical trials and preclinical research required to develop innovative treatments for a wide range of diseases.

Additionally, the site will be instrumental in producing the materials needed for gene therapies and genetically modified cell therapies, two promising fields with the potential to revolutionize medicine.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.